The ameliorating effect of AMY against NAFLD appeared to simulate fenofibrate, a known lipid-lowering drug used as a control, which is in fact a PPAR-α agonist that functions through the activation of lipoprotein lipase, and by inducing changes in the transcription of genes encoding enzymes involved in lipid and lipoprotein metabolism (39). The gene discussed is LPL; the disease is metabolic dysfunction-associated steatotic liver disease.